Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC-102 in combat-related PTSD
NCT02384369Phase 2Withdrawn
- Sponsor
- Synchroneuron Inc.
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of acamprosate in post-traumatic stress disorder (PTSD), sponsored by Synchroneuron Inc.. Planned start Jun 2016; status: withdrawn.
02
Drugs
acamprosate
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT02384369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384369.